EUVIMEDEUVIMED entdecken
EditorialKommentar

Cardiac Reverse Remodelling with Vericiguat: Victory or no Victory?

Muhammad Shahzeb Khan, Paul A Grayburn, Javed Butler

European Journal of Heart Failure · 2023

DOI: 10.1002/ejhf.2883 ↗

Kurz gefasst

Editorial in der Zeitschrift European Journal of Heart Failure, 2023. Verfasst von Muhammad Shahzeb Khan und 2 weiteren Autor:innen. Beteiligte Einrichtung: Division of Cardiology, Duke University, Durham, NC, USA. Hauptthemen laut MEDLINE: Heart Failure, Heterocyclic Compounds, 2-Ring. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 14 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Heart FailureHeterocyclic Compounds, 2-RingHumansHeartPyrimidines

Substanzen

vericiguatHeterocyclic Compounds, 2-RingPyrimidines

Autor:innen und Institutionen

  • Division of Cardiology, Duke University, Durham, NC, USA.
  • Baylor Scott and White Heart Hospital Plano, Plano, TX, USA.
  • Baylor Scott and White Research Institute, Dallas, TX, USA.
  • Department of Medicine, University of Mississippi, Jackson, MS, USA.

Zitieren

APA

Khan, M. S., Grayburn, P. A., & Butler, J. (2023). Cardiac Reverse Remodelling with Vericiguat: Victory or no Victory?. European Journal of Heart Failure. https://doi.org/10.1002/ejhf.2883

Vancouver

Khan MS, Grayburn PA, Butler J. Cardiac Reverse Remodelling with Vericiguat: Victory or no Victory?. European Journal of Heart Failure. 2023. doi:10.1002/ejhf.2883

BibTeX
@article{Khan2023,
  author = {Khan, Muhammad Shahzeb and Grayburn, Paul A and Butler, Javed},
  title = {Cardiac Reverse Remodelling with Vericiguat: Victory or no Victory?},
  journal = {European Journal of Heart Failure},
  year = {2023},
  doi = {10.1002/ejhf.2883}
}
Kostenlos starten →